The alternative axis of renin angiotensin system, ACE2/Angiotensin-(1-7)/Mas receptor, has attracted massive interest among academia and industry. Originally seen as counterbalancing the ACE/Ang II axis in cardiovascular system, increased understanding of the biologic effects of Angiotensin-(1-7) has shown that this pathway is relevant for diseases of other organ systems including hematologic, neurologic, vascular, musculoskeletal and metabolic disorders. Advancements range from it’s interaction with gut-microbiome and non-addictive analgesia to stimulation of endothelial cells and their progenitors for the treatment of ischemic disorders. This symposium will update the ASPET community with the recent advancements and discuss novel hypotheses and pharmacotherapeutic opportunities.